Tazemetostat Active in Non-Hodgkin Lymphomas, Solid Tumors

Share this content:
The recommended phase 2 dose is 800 mg twice daily.
The recommended phase 2 dose is 800 mg twice daily.

Tazemetostat may be safe and effective in some patients with non-Hodgkin lymphomas or solid tumors, according to research published in The Lancet Oncology.1

Tazemetostat, a selective inhibitor of EZH2, showed preclinical activity against EZH2­-mutant non-Hodgkin lymphomas, INI1-negative rhabdoid tumors, and SMARCA4-negative rhabdoid tumors of the ovary. For this phase 1 study (ClinicalTrials.gov Identifier: NCT01897571), researchers enrolled patients with relapsed/refractory non-Hodgkin lymphoma or locally advanced/metastatic tumors to assess the drug's safety and efficacy.

Sixty-four patients were enrolled between 2013 and 2016; 21 had B-cell non-Hodgkin lymphoma (13 had diffuse large B-cell lymphoma, 7 had follicular lymphoma, and 1 had marginal zone lymphoma), and 43 had a solid tumor. In the lymphoma and solid tumor groups, the median ages were 62 and 55 years, respectively, and all patients had a median 3 prior lines of therapy.

The most frequently noted treatment-related adverse events (AEs) were asthenia (33%), anemia (14%), muscle spasms (14%), nausea (13%), vomiting (9%), and anorexia (6%), though most were grade 1 or 2.

Grade 3 to 4 treatment-related AEs, although uncommon, were noted: thrombocytopenia (4%), neutropenia (4%), hepatocellular injury (2%), and hypertension (2%). The cases of grade 4 thrombocytopenia were dose-limiting; the recommended phase 2 dose was set at 800 mg twice daily.

Seven patients died on study, though no deaths were treatment-related.

Complete or partial responses were noted in 38% of patients with non-Hodgkin lymphoma and in 5% of patients with a solid tumor.

The authors concluded that “tazemetostat inhibits EZH2, as evidenced by reduction of trimethylation of H3K27, and can induce durable tumour responses in patients with B-cell non-Hodgkin lymphoma and INI1-negative or SMARCA4-negative tumours with a favourable safety profile.” Phase 2 studies are ongoing.


  1. Italiano A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018 Apr 9. doi: 10.1016/S1470-2045(18)30145-1

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Cancer Therapy Advisor Articles